Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness - 22025 Was Another Exceptionally Hot Year
- 310 High priority Contraptions for Tech Aficionados
- 46 Objections for an Ocean side Wedding
- 5Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Manual for Savvy Home Lighting Framework: Lights up Your Space
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- German official report: Teen social media ban faces legal hurdles
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Conquering Social Generalizations: Individual Accounts of Strengthening
- What to know about cheese voluntarily recalled in 20 states
